LON:MPH

Mereo BioPharma Group plc (MPH.L) (MPH) Share Forecast, Price & News

GBX 26.50

-0.50 (-1.85%)

(As of 12/17/2020)

Compare

Today's Range: 26
▼
26.50
50-Day Range: 26.50
▼
26.50
52-Week Range: 13
▼
60

Volume: 49,264 shs
Average Volume: 333,975 shs
Market Capitalization: £89.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Insider Trades Headlines

About Mereo BioPharma Group plc (MPH.L) (LON:MPH) Stock

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Receive MPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group plc (MPH.L) and its competitors with MarketBeat's FREE daily newsletter.

MPH Stock News Headlines

May 31, 2023 | technews.tmcnet.com

Mereo BioPharma to Present at the Jefferies Healthcare Conference

May 29, 2023 | msn.com

Navigating Mereo BioPharma's Future: Risky Proposition Despite Strides In Rare Disease Treatment

June 3, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 5, 2023 | msn.com

Mereo BioPharma transfers ADS listing from Nasdaq Global Market to Nasdaq Capital Market

May 5, 2023 | technews.tmcnet.com

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

March 28, 2023 | benzinga.com

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

March 21, 2023 | msn.com

Mereo soars ~25% after FDA, EMA guidance on main goals of trial for lung disease drug

December 21, 2022 | benzinga.com

Short Volatility Alert: Mereo Biopharma

June 3, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

October 28, 2022 | technews.tmcnet.com

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

October 17, 2022 | marketwatch.com

Mereo BioPharma Gets FDA Fast-Track Designation for Alvelestat >MREO

October 17, 2022 | markets.businessinsider.com

Mereo BioPharma: FDA Grants Fast Track Designation For Alvelestat - Quick Facts

October 5, 2022 | marketwatch.com

Rubric Capital Management Increases Slate of Proposed Mereo BioPharmaDirector Nominees to Five

September 26, 2022 | benzinga.com

Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board

September 22, 2022 | seekingalpha.com

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

September 13, 2022 | yahoo.com

Titus Welliver Joins Titans Season 4 as Lex Luthor, November Premiere Set

August 23, 2022 | seekingalpha.com

Mereo cites 'deficiencies' in investor Rubric's letter seeking general meeting, removal of directors

July 5, 2022 | finance.yahoo.com

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

June 17, 2022 | finance.yahoo.com

Why Mereo BioPharma Shares Are Jumping Today

June 17, 2022 | seekingalpha.com

Mereo BioPharma: Activist Pressure In A Net-Net Biopharma

May 17, 2022 | markets.businessinsider.com

Alliance Pharma To Acquire LGC's Bio-analytical Business Arm For Undisclosed Sum

May 11, 2022 | finance.yahoo.com

ARTRYA SIGNS FIRST U.S. HOSPITAL CLINICAL PARTNERSHIP WITH HUNTSVILLE HEART CENTER

May 11, 2022 | finance.yahoo.com

New Research Continues to Reinforce Effectiveness of Massage Therapy for Relief of Chronic Pain

May 7, 2022 | tmcnet.com

Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from "ASTRAEUS" Phase 2 Study of Alvelestat

June 2, 2021 | msn.com

BRIEF-Mereo Biopharma Announces Positive Desmosine Biomarker Data From An Interim Analysis Of An Investigator Initiated Study Of Alvelestat In Bronchiolitis Obliterans Syndrome ...

April 18, 2021 | investing.com

Mereo BioPharma Group PLC ADR (MREO)

March 31, 2021 | finance.yahoo.com

Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights

See More Headlines

MPH Price History

30 days | 90 days | 365 days | Advanced Chart

MPH Company Calendar

Last Earnings: 9/29/2020
Today: 6/03/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:MPH
CUSIP: N/A
CIK: N/A
Web: mereobiopharma.com
Phone: 44 33 3023 7300
Fax: N/A
Employees: 50
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 164.26
Current Ratio: 2.98
Quick Ratio: 2.92

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: GBX 17.12 per share
Price / Cash Flow: 1.55
Book Value: GBX 7.20 per share
Price / Book: 3.68

Miscellaneous

Outstanding Shares: 338,713,984
Free Float: N/A
Market Cap: £89.76 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Denise Scots-Knight (Age 61)
Co-Founder, CEO & Exec. Director
Comp: $751.37k

Mr. Charles Sermon (Age 51)
Co-Founder, Gen. Counsel & Company Sec.
Comp: $545.68k

Dr. Alastair MacKinnon (Age 50)
Co-Founder & Chief Medical Officer
Comp: $540.12k

Mr. John Richard (Age 63)
Co-Founder & Head of Corp. Devel.
Comp: $512.99k

Mr. Michael Stephen Wyzga MBA (Age 65)
Interim CFO & Exec. Director
Comp: $27.59k

Ms. Alexandra Hughes-Wilson (Age 49)
Head of Patient Access & Commercial Planning
Comp: $265.93k

Ms. Jill Henrich (Age 57)
US Site Head & Sr. VP of Regulatory Affairs
Comp: $286.93k

Dr. John A. Lewicki (Age 68)
Chief Scientific Officer

Dr. Fiona Bor
Head of Intellectual Property

Mr. Ian Hodgson
Head of Clinical Operations

Key Competitors

View All Competitors

MPH Stock - Frequently Asked Questions

How have MPH shares performed in 2023?: Mereo BioPharma Group plc (MPH.L)'s stock was trading at GBX 26.50 on January 1st, 2023. Since then, MPH shares have increased by 0.0% and is now trading at GBX 26.50.
View the best growth stocks for 2023 here.
How were Mereo BioPharma Group plc (MPH.L)'s earnings last quarter?: Mereo BioPharma Group plc (MPH.L) (LON:MPH) issued its quarterly earnings results on Tuesday, September, 29th. The company reported ($105.00) earnings per share (EPS) for the quarter.
What other stocks do shareholders of Mereo BioPharma Group plc (MPH.L) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group plc (MPH.L) investors own include Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Inovio Pharmaceuticals (INO), Micron Technology (MU), Tesla (TSLA), Amgen (AMGN), ARMOUR Residential REIT (ARR), Arena Pharmaceuticals (ARNA) and Ardelyx (ARDX).
What is Mereo BioPharma Group plc (MPH.L)'s stock symbol?: Mereo BioPharma Group plc (MPH.L) trades on the London Stock Exchange (LON) under the ticker symbol "MPH."

How do I buy shares of Mereo BioPharma Group plc (MPH.L)?: Shares of MPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Mereo BioPharma Group plc (MPH.L)'s stock price today?: One share of MPH stock can currently be purchased for approximately GBX 26.50.
How much money does Mereo BioPharma Group plc (MPH.L) make?: Mereo BioPharma Group plc (MPH.L) (LON:MPH) has a market capitalization of £89.76 million.
How can I contact Mereo BioPharma Group plc (MPH.L)?: Mereo BioPharma Group plc (MPH.L)'s mailing address is 1 Cavendish Place, LONDON, W1G 0QF, United Kingdom. The official website for the company is mereobiopharma.com. The company can be reached via phone at 44 33 3023 7300.

This page (LON:MPH) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial